市值38.4亿美元的Akero Therapeutics, Inc. (NASDAQ:AKRO)董事Jane Henderson于2025年8月12日以每股47.457美元的价格出售了3,000股普通股，总价值为142,371美元。尽管该股票在过去一周下跌了9%，但在过去一年中表现出色，回报率达94%。 同一天，Henderson还行权获得了3,000股Akero Therapeutics普通股， ...

Akero Therapeutics (NASDAQ: AKRO )首席科学官Timothy Rolph于2025年8月5日出售了12,500股普通股，总价值616,299美元。这些交易分两次执行，价格在49.065美元至49.494美元之间。根据 InvestingPro 数据，该股票表现出色，过去一年上涨超过122%，目前股价接近52.79美元。

2025年8月12日， Akero Therapeutics（AKRO）披露2笔公司内部人交易情况。董事Henderson Jane于2025年8月12日卖出3000股。 2025年8月12日 董事 Henderson Jane 2025年8月12日 卖出 3000 47.46 14.24万 2025年8月12日 董事 Henderson Jane 2025年8月12日 买入 3000 7.01 ...

Akero Therapeutics (AKRO.US)表示，其药物efruxifermin (EFX)改善了肝纤维化，但没有加重肝脏疾病，达到了2b期研究的主要目标。

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Week 96 data presented during a late-breaking oral session at EASL 2025 demonstrated the potential of EFX 50mg to reverse cirrhosis in high-need MASH subgroups, including patients with cryptogenic ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

The positions in the table below reflect the Akero Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

Akero Therapeutics Inc 图表 当前市场的图表，可体现某段时间内的市场价格变动。可用于查看市场走势。 IG客户在该市场上持有多头或空头仓位的百分比。此项计算精确至1% 此价格已延迟至少 15 分钟。 如果您的总仓位大于第 1 级 ...

Find the latest Financials data for Akero Therapeutics, Inc. Common Stock (AKRO) at Nasdaq.com.

Akero Therapeutics has been a focus of several analyst firms. Canaccord Genuity maintained a Buy rating on the company's stock, noting the potential of the drug candidate, Efruxifermin.

Article ‘Count’ and ‘Share’ for Akero Therapeutics based on listed parameters only. The articles listed below published by authors from Akero Therapeutics, organized by journal and article ...